1. Home
  2. SLRX vs CINGW Comparison

SLRX vs CINGW Comparison

Compare SLRX & CINGW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLRX
  • CINGW
  • Stock Information
  • Founded
  • SLRX N/A
  • CINGW N/A
  • Country
  • SLRX United States
  • CINGW United States
  • Employees
  • SLRX N/A
  • CINGW 13
  • Industry
  • SLRX Biotechnology: Pharmaceutical Preparations
  • CINGW Biotechnology: Pharmaceutical Preparations
  • Sector
  • SLRX Health Care
  • CINGW Health Care
  • Exchange
  • SLRX Nasdaq
  • CINGW Nasdaq
  • Market Cap
  • SLRX N/A
  • CINGW N/A
  • IPO Year
  • SLRX N/A
  • CINGW 2021
  • Fundamental
  • Price
  • SLRX $0.68
  • CINGW $0.04
  • Analyst Decision
  • SLRX
  • CINGW
  • Analyst Count
  • SLRX 0
  • CINGW 0
  • Target Price
  • SLRX N/A
  • CINGW N/A
  • AVG Volume (30 Days)
  • SLRX 592.7K
  • CINGW N/A
  • Earning Date
  • SLRX 05-12-2025
  • CINGW N/A
  • Dividend Yield
  • SLRX N/A
  • CINGW N/A
  • EPS Growth
  • SLRX N/A
  • CINGW N/A
  • EPS
  • SLRX N/A
  • CINGW N/A
  • Revenue
  • SLRX N/A
  • CINGW N/A
  • Revenue This Year
  • SLRX N/A
  • CINGW N/A
  • Revenue Next Year
  • SLRX N/A
  • CINGW N/A
  • P/E Ratio
  • SLRX N/A
  • CINGW N/A
  • Revenue Growth
  • SLRX N/A
  • CINGW N/A
  • 52 Week Low
  • SLRX $0.45
  • CINGW N/A
  • 52 Week High
  • SLRX $7.20
  • CINGW N/A
  • Technical
  • Relative Strength Index (RSI)
  • SLRX 38.70
  • CINGW N/A
  • Support Level
  • SLRX $0.61
  • CINGW N/A
  • Resistance Level
  • SLRX $0.72
  • CINGW N/A
  • Average True Range (ATR)
  • SLRX 0.10
  • CINGW 0.00
  • MACD
  • SLRX 0.02
  • CINGW 0.00
  • Stochastic Oscillator
  • SLRX 56.53
  • CINGW 0.00

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: